Presentation ACC 2024 Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial Presenter: David E. Kandzari April 08, 2024
Presentation ACC 2024 Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial Presenter: Alexander Fanaroff April 07, 2024
Presentation ACC 2024 Main Results From The Step-hfpef Dm Trial Presenter: Mikhail Kosiborod April 06, 2024
Presentation ACC 2024 Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Presenter: Michael J. Koren April 06, 2024
Presentation THT 2024 Shock-Phenotype Matching Using Real-World Evidence: A New Paradigm for Prospective Enrollment in Clinical Trials of Acute MCS Devices in Cardiogenic Shock Presenter: James W. Schurr March 06, 2024
Presentation THT 2024 The Conundrum of Clinical Trials in Cardiogenic Shock Presenter: JoAnn Lindenfeld March 06, 2024
Presentation THT 2024 Impact Of Rapid Up-Titration of Guideline-Directed Medical Therapies On Quality of Life: Insights From The STRONG-HF Trial Presenter: Kamile Cerlinskaite-Bajore March 06, 2024
Presentation THT 2024 AI Assisted Identification of Super responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial Presenter: Deya Alkhatib March 06, 2024
Presentation THT 2024 Remote Management of Sitting Pulmonary Artery Pressures Tested Against a Performance Goal of Reduced HF Hospitalizations and All-cause Mortality in a Prospective Multi-Center Open Label PROACTIVE-HF Trial in NYHA Class III Heart Failure Presenter: Liviu Klein March 05, 2024
Presentation THT 2024 Pulmonary Artery Catheter in Shock (PACCS) Presenter: Shashank Shekhar Sinha March 05, 2024
Presentation THT 2024 Short-term Atrial Shunt Device-Induced Changes in Cardiac Structure/Function and Risk of Subsequent Heart Failure Events: Findings from the REDUCE-LAP HF II Randomized Clinical Trial Presenter: David M. Kaye March 05, 2024
Presentation THT 2024 ECMO-Unload: Is This the Answer to ECLS-SHOCK? Presenter: Dirk Westermann March 05, 2024
Presentation THT 2024 DoReMe: Are Inotropes Helpful or Harmful? Presenter: Benjamin Hibbert March 05, 2024
Presentation THT 2024 Inotropes and Mortality in Patients With Cardiogenic Shock Due to Myocardial Infarction: Insights from the SWEDEHEART Registry Presenter: Elmir Omerovic March 05, 2024
Presentation THT 2024 Risk Stratification: Thinking Beyond SCAI Staging Presenter: David A. Baran March 05, 2024
Presentation THT 2024 Clinical Trials for Cardiogenic Shock: Going Forwards, Backwards, or Sideways? Presenter: Mariell Jessup March 05, 2024
Presentation THT 2024 Designing Clinical Trials to Facilitate Better Implementation: Tips for Researchers Presenter: Harriette G.C. Van Spall March 05, 2024
Presentation THT 2024 Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results Presenter: Sanjiv J. Shah March 05, 2024